Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0270
-0.0010 (-3.57%)
Sep 1, 2025, 1:17 PM AEST
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 13.40M AUD with 584.21% growth. Radiopharm Theranostics had revenue of 10.96M in the half year ending June 30, 2025, with 462.79% growth.
Revenue
13.40M
Revenue Growth
+584.21%
P/S Ratio
4.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
66.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 13.40M | 11.44M | 584.21% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.84B |
| Telix Pharmaceuticals | 1.01B |
| Ansell | 3.06B |
| Mesoblast | 26.23M |
Radiopharm Theranostics News
- 5 months ago - Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting - Seeking Alpha
- 6 months ago - This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga